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Objective. To determine the utility and cost effectiveness of preoperative computed tomography (CT) in detecting disease extent in patients
with uterine carcinoma.
Methods.Medical records of 762 patients with uterine malignancies at hysterectomy from 1990–2006 were reviewed. Study inclusion required
preoperative abdominal-pelvic CT scan. All CT findings were correlated with intraoperative and pathologic data. Statistical analysis was
performed using Fisher's exact test. Cost analysis was based on Medicare fee schedules.
Results. 250 subjects (33%), who underwent preoperative CT, comprised the study cohort. CT suggested metastases in 22 (9%) cases and
altered management in 7 (3%). Incidental findings were noted in 43 cases (17%), and altered management in 7 (3%). Among complex atypical
hyperplasia (CAH) and grade 1 endometrioid cancers, CT suggested metastases in 9% and demonstrated other incidental findings in 21%;
management was altered in just 4% of patients. Similarly, among grade 2/3 endometrioid tumors, CT suggested metastases in 7%, and incidental
findings in 14%; management was altered in 4% of cases. For high-risk histologies, CT altered management in 11% of papillary serous and clear
cell cases and in 13% of sarcomas. CT findings more often altered management in women with high-risk histologies than in those with
endometrioid carcinomas (p=0.05). Expenditure of $17,622 for CT imaging is required to alter management of one patient.
Conclusions. Preoperative CT is costly, and rarely alters management in patients with uterine neoplasms, particularly among endometrioid
carcinomas. CT may be beneficial in patients with high-risk histologies and requires further study.
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Endometrial cancer is the fourth most common malignancy
in women and the most common gynecologic cancer, account-
ing for about 6% of cases [1]. In 2007, an estimated 39,080
cases of uterine corpus malignancies were diagnosed in the
United States, with approximately 7400 deaths from the disease⁎ Corresponding author. Division of Gynecologic Oncology, Department of
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Open access under CC BY-NC-ND license[1]. The five year survival rate for local disease is 96%. How-
ever, five year survival rates decrease dramatically for women
with regional and distant disease to 67% and 23%, respectively
[1]. In 1988, the International Federation of Obstetrics and
Gynecology (FIGO) introduced a surgical staging system for
endometrial cancer. Primary treatment now includes total hys-
terectomy, bilateral salpingo-oophorectomy, pelvic and para-
aortic lymphadenectomy, and peritoneal cytology.
Although most patients with endometrial cancer present with
early stage disease, approximately 12% of women with tumors
clinically confined to the uterus will have evidence of lymph
node metastases at the time of surgery and still others will have
occult adnexal or peritoneal involvement [2–3]. The frequency
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differentiated or deeply myoinvasive tumors and in those with
high-risk histologic subtypes [2–3]. Unfortunately, prediction
of depth of invasion and tumor grade, preoperatively, are often
inaccurate in determining final tumor grade and stage [4–7].
Given the difficulty in predicting nodal metastases based on
pathologic risk factors, interest has focused on the identification
of non-invasive imaging modalities to detect nodal disease.
Conventional imaging techniques such as computed tomogra-
phy (CT) and magnetic resonance imaging (MRI) rely on
increased nodal size to predict the presence of metastatic
disease, but have demonstrated relatively low sensitivity for the
detection of pelvic and para-aortic nodal involvement [8–9].
More recent studies using functional imaging such as positron
emission tomography (PET) with 2-[18F] fluoro-2-deoxy-D-
glucose (FDG), and combined PET/CT have demonstrated only
moderate sensitivity in predicting lymph node metastases
preoperatively. Moreover, the relative benefit and cost effec-
tiveness of PET and PET/CT remain in question [10–11].
Given our limited ability to detect nodal metastases there has
been a shift towards surgical staging in all women with
endometrial cancer [12–13]. Comprehensive staging is highly
prognostic and allows for tailored postoperative therapy. The
routine use of lymphadenectomy in all women renders pre-
operative findings of lymphadenopathy irrelevant. Thus, the
potential benefit of radiologic imaging rests with the detection
of extra-nodal metastatic disease or other incidental findings
that alter surgical planning.
The goal of the present study was to examine the utility of
computed tomography for women with endometrial cancer.
Specifically, we sought to determine the ability of CT to detect
extra-nodal metastatic disease and to identify other incidental
findings that altered patient management. A secondary
objective of the study was to examine the cost effectiveness
of CT imaging in women with endometrial cancer.
Materials and methods
After Institutional Review Board approval was obtained a
retrospective review of women with tumors of the uterine
corpus identified at the time of hysterectomy was performed.
Patients who underwent surgery between January 1, 1990 and
December 31, 2006 at Columbia University Medical Center-
New York Presbyterian Hospital were included. Women who
underwent preoperative abdominal-pelvic computed tomogra-
phy at our institution were selected for further analysis.
Demographic, clinical and pathologic characteristics were
determined through review of medical records. Follow-up was
ascertained from institutional databases.
The decision to perform preoperative abdominal and pelvic
CT scan was at the discretion of the evaluating physician. Each
patient underwent abdominal and pelvic CT after the adminis-
tration of oral and intravenous contrast. Sequential 5 mm
sections were obtained. Radiographs were reviewed in a
standard clinical manner by an attending radiologist. Pelvic
and para-aortic nodes were considered enlarged if they
exceeded 1.0 cm in diameter. Radiographic data abstractedincluded the type of preoperative studies performed, and all
reported findings including lymph node size and location,
coincident benign and pathologic findings, metastatic sites, and
other upper abdominal benign or malignant findings.
Analysis focused on the identification of extra-nodal
metastatic disease and on the identification of significant
incidental findings. Extra-nodal metastatic disease included any
CT finding of tumor within the peritoneal cavity or abdominal
viscera exclusive of the pelvic and para-aortic lymph nodes.
Incidental findings consisted of abnormalities on CT scan that
were unrelated to the primary cancer or spread from the tumor.
For all patients we determined whether the CT findings altered
management. Altered management consisted of performance of
an additional surgical procedure, biopsy or other intervention.
Our study period encompasses sixteen years, and all patients
underwent total abdominal hysterectomy and bilateral salpingo-
oophorectomy, however complete lymphadenectomy was not
standard practice for the entire study period. The decision to
perform lymph node sampling was at the discretion of the
treating physician. Since it is now recommended that all women
in the U.S. undergo lymphadenectomy we did not analyze the
ability of CT to detect nodal disease.
For each patient the surgical findings and final pathology
were correlated with the CT results. The proportion of patients
with metastatic disease and patients with incidental findings,
that altered management, was then calculated. Patients were
stratified by histology and tumor grade to identify subgroups of
patients in which CT was most useful. Statistical analysis was
performed using Fisher's exact test. A p-value of b0.05 was
considered statistically significant.
Cost analysis was based on publishedMedicare fee schedules
for 2008. The combined reimbursement rate for an abdominal
and pelvic CT scan, with and without oral and intravenous
contrast is $844.44. The total radiologist reimbursement rate for
reading and interpretation of the CT scan is $142.44. Thus, the
total cost for an abdominal-pelvic CT scan, based on the 2008
Medicare reimbursement schedule for New York, New York, is
$986.88. In order to obtain a more accurate estimate of cost
effectiveness, and the actual burden of dollars on the healthcare
system, we used this total cost in subsequent analysis.
Results
A total of 762 patients with endometrial cancer were
identified. Preoperative CT was performed in 250 (33%)
subjects. These 250 women comprise the study cohort. The
demographic characteristics of the study population are
displayed in Table 1. The median age was 68. The preoperative
histologic diagnosis consisted of endometrioid tumors in 166
(66%), uterine sarcomas in 32 (13%), clear cell and serous
tumors in 28 (11%) and endometrial hyperplasia in 12 (5%).
Among women with endometrioid tumors, grade 1 lesions were
most common. Preoperative endometrial sampling was inde-
terminate in 8 (3%) patients and not performed in 4 (2%). Lymph
node sampling was performed in 104 (41%) patients. The stage
distribution of the cohort consisted of: 182 (73%) stage I, 23
(9%) stage II, 27 (11%) stage III and 12 (5%) stage IV.
Table 2
Characteristics of patients in whom CT findings altered management
Preoperative diagnosis Location of abnormalities
on CT scan
Management
Extra-nodal metastatic disease
Grade 1 endometrioid Omentum Omentectomy
Grade 1 endometrioid Omentum Omentectomy
Grade 3 endometrioid Omentum Omentectomy
Grade 3 endometrioid Omentum Omentectomy
Grade 3 endometrioid Peritoneal/small intestine Small bowel resection
Grade 3 endometrioid Peritoneal/large intestine Rectosigmoid resection/
ileostomy
Sarcoma Liver Palpable liver nodules
Incidental findings
Grade 1 endometrioid Diverticular disease
of rectosigmoid
Rectosigmoid resection
Grade 1 endometrioid Renal mass Intraoperative biopsy
Grade 2 endometrioid Renal mass Ultrasound and biopsy
Grade 2 endometrioid Renal mass Ultrasound and biopsy
Grade 3 endometrioid Retroperitoneal
mass/hydronephrosis
Preoperative ureteral
stent/biopsy of mass
Sarcoma Renal mass Ultrasound and biopsy
Sarcoma Renal mass Ultrasound and biopsy
Table 1
Demographic characteristics of the study population
Study subjects (n=250)
Age
Median 68
Range 30–90
Race
White 128 (51)
Black 45 (18)
Hispanic 45 (18)
Other 32 (13)
Preoperative diagnosis
Complex atypical hyperplasia 12 (5)
Grade 1 endometrioid carcinoma 82 (33)
Grade 2 endometrioid carcinoma 46 (18)
Grade 3 endometrioid carcinoma 46 (18)
Papillary serous/clear cell carcinoma 28 (11)
Sarcoma 32 (13)
Indeterminate 8 (3)
Unavailable 4 (2)
Stage
IA 23 (9)
IB 116 (46)
IC 43 (17)
II 23 (9)
III 27 (11)
IV 12 (5)
Final histologic diagnosis
Endometrioid 172 (69)
Papillary serous/clear cell 33 (13)
Sarcoma 44 (18)
Final pathologic grade
1 93 (37)
2 42 (17)
3 114 (46)
Lymphvascular space invasion
Yes 61 (24)
No 24 (10)
Unknown 165 (66)
(%)
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nodal metastatic disease in 22 (9%) cases and patient manage-
ment was altered due to these findings in 7 (3%) cases. Sites of
extra-nodal disease were the adnexa in 10 patients, omentum in
4 patients, liver in 4 patients, bowel in 3 patients, and 1 patient
with large volume ascites. The sensitivity of CT scan for
predicting extra-nodal metastatic disease was 37.5%, and the
specificity was 94.2%. The positive predictive value of CT scan
in predicting extra-nodal disease is 41%, and the negative
predictive value is 93%.
Incidental findings were noted in 43 cases (17%). Incidental
findings included benign appearing liver and renal cysts, renal
masses, splenic cysts, adrenal adenomas, hydronephrosis,
pelvic/adnexal cysts, retroperitoneal mass and diverticular
disease of the rectosigmoid colon. These findings were con-
sidered significant and altered patient management in 7 (3%)cases. Patients for whom CT findings altered management are
characterized in Table 2. Interestingly, 5 of the 7 cases had a
renal mass that was suspicious of carcinoma. In each of these
patients, renal biopsy was performed which confirmed diag-
nosis of second primary renal cell carcinoma. One patient had
significant diverticular disease of the rectosigmoid colon. For
this patient, a preoperative colorectal surgery consult was ob-
tained and the patient underwent a low anterior resection with
diverting ileostomy. The last significant incidental finding was a
large retroperitoneal mass that was obstructing the ureter and
causing hydronephrosis and a perinephric urinoma. This patient
had a ureteral stent and biopsy of the mass preoperatively which
confirmed a diagnosis of squamous cell carcinoma. Overall, 14
(5.6%) patients had management altered as a result of findings
(extra-nodal metastatic disease or incidental findings) reported
on preoperative CT scan.
Patients were then stratified based on their preoperative
histologic diagnosis in order to identify subsets of patients who
may benefit from preoperative staging CT. For patients with
CAH and grade 1 endometrioid cancers, CT was suggestive of
metastatic disease in 9 (8.5%) patients and demonstrated other
incidental findings in 20 (21.3%) patients. However, patient
management was altered in just 4 (4.3%) patients. Similarly, for
patients with grade 2 and 3 endometrioid tumors, metastatic
disease was suggested in 6 (7.1%) patients, incidental findings
noted in 12 (14.3%) and management altered due to these
findings in 3 (3.6%) cases. Among patients with high-risk his-
tologic subtypes, CT was suggestive of metastatic disease in 5
(8.3%) cases, and demonstrated other incidental findings in 5
(8.3%) cases. CT altered management in 3 (10.7%) women with
papillary serous and clear cell tumors and in 4 (12.5%) women
with uterine sarcomas. CT findings were more likely to alter
management in women with high-risk histologic subtypes than
in those with endometrioid carcinomas (p=0.05).
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care fee schedules for 2008. We were interested in obtaining the
current cost effectiveness for CT scan in patients with endo-
metrial cancer, as well as an estimate based on the actual burden
to the healthcare system. The published Medicare reimburse-
ment rate for an abdominal-pelvic CT scan is $844.44 and
$142.44 for interpretation, for a total cost of $986.88. The total
cost of CT scan and interpretation was then calculated for the
study cohort at $246,720. Assuming a positive rate of iden-
tifying metastases and other incidental findings which would
alter patient management of 5.6%, as reported in our study, 17.9
women would need to undergo CT to detect one abnormality at
a cost of $17,622 per abnormality. When restricted to the iden-
tification of extra-nodal metastatic disease the cost increases to
$35,245 for the identification of one patient with extra-nodal
metastatic disease.
Discussion
The results of our study indicate that the routine performance
of preoperative CT imaging for patients with uterine corpus
malignancies is costly and rarely alters management. The utility
of preoperative CT was particularly limited in women with
endometrioid tumors; CT altered management in just 7 patients
(4%). The performance of preoperative CT may have some
benefit for patients with high-risk histologic subtypes, as these
tumors tend to be more aggressive and thus have a greater
propensity for extra-nodal disease.
Results of previous studies have addressed the utility of CT
imaging preoperatively for patients with uterine malignancies
[8,14–17]. The most recent series by Connor et al evaluates the
utility of preoperative CT for detection of nodal metastases and
found that the sensitivity was 57% and the specificity was 92%.
Management was altered in just 8% of patients. Numerous other
studies have evaluated the ability of CT to detect myometrial
invasion [5,18–21]. The accuracy of CT prediction of myometrial
invasion has been reported at 67–76% [18–21]. T2 or contrast
enhanced MRI techniques yield similar accuracy in predicting
myometrial invasion [9,18–22]. While preoperative knowledge
of tumor grade and depth of invasion may help predict patients at
risk of lymph node metastases and extra-nodal disease, the utility
of imaging for this purpose is in question since all patients should
ultimately undergo comprehensive surgical staging.
Preoperative knowledge of lymph node status, and distant
metastatic disease may be helpful in directing optimal surgical
management and adjuvant therapy when needed. Many women
with endometrial cancer are still managed by a general
gynecologist, and preoperative assessment of metastatic disease
may facilitate transfer of these patients to care by a gynecologic
oncologist. Initial management of endometrial cancer patients
by a gynecologic oncologist is paramount as the quality and
completeness of surgical staging may provide a survival
advantage, offer an efficient use of healthcare resources and
minimize potential morbidity of adjuvant treatment [12–13].
The American College of Obstetricians and Gynecologists
acknowledges that referral to a gynecologic oncologist is
recommended for complete and adequate surgical staging, high-risk histologic subtypes, patients with extrauterine disease or
positive peritoneal cytology, recurrent disease, patients in whom
nonoperative therapy is contemplated, and for patients with an
incidental finding of endometrial cancer following hysterect-
omy for other indications [12]. Furthermore, due to risk factors
for endometrial cancer such as obesity, diabetes, and hyperten-
sion, many patients diagnosed with endometrial cancer have
comorbidities that may increase their surgical risk, and
preoperative knowledge of metastatic disease sites may guide
surgery and treatment planning. Additionally, patients with
extrauterine disease benefit from optimal cytoreduction, and
have a survival advantage [23–26]. Bristow et al in a study of 65
patients with stage IV endometrial cancer found that optimal
cytoreduction was associated with a median survival of
34.3 months, which was a statistically significant advantage
compared to suboptimally cytoreduced patients who had a
median survival of 11.0 months [24]. Similarly, in a series of 55
patients with stage IV endometrial cancer, Chi and colleagues
found that patients who underwent optimal cytoreduction had a
median survival of 31 months, compared to 12 months with
suboptimal cytoreduction and 3 months with no cytoreduction
[25]. Therefore, preoperative knowledge of extra-nodal disease
could facilitate referral of patients to a gynecologic oncologist
prepared to perform a cytoreductive procedure. If all patients
with endometrial cancer are managed by a gynecologic
oncologist, however, the utility of preoperative CT for this
indication is of limited usefulness.
In our study, we examined the rate of detection of incidental
findings on preoperative staging CT, and the incidence of these
findings altering patient management. We noted incidental
findings of liver and renal cysts, renal masses, splenic cysts,
adrenal adenomas, hydronephrosis, pelvic/adnexal cysts, retro-
peritoneal mass and diverticular disease of the rectosigmoid
colon in 43 cases (17%). These findings were considered signi-
ficant and altered patient management in 7 (3%) cases. Inte-
restingly, 5 of these 7 patients had suspicious renal masses that
after evaluation were found to be consistent with second primary
renal cell carcinoma. Moreover the preoperative diagnosis for
these patients ranged from grade 1 endometrioid carcinoma to
sarcoma. While there may be some utility for preoperative
imaging for patients with high-risk histologic subtypes, we did
not find this to be the case for endometrioid tumors.
The primary outcome measured was findings of metastatic
disease or incidental findings on CT. We report a sensitivity of
CT scan for identifying metastatic disease at 37.5%, and a
specificity of 94%. In our series, management was altered based
on CT findings of metastatic disease or incidental findings in
just 3% of patients. Our study is limited by its retrospective
nature. Also, we cannot exclude a potential selection bias in that
the performance of CT scan was at the discretion of the treating
gynecologic oncologist. Finally, a bias exists in that our study
only considers those patients who underwent initial surgical
management for uterine carcinoma. Our study does have the
benefit of a large series of patients, and it analyzes the utility of
identifying metastases preoperatively. Also, our cohort of
patients is from a tertiary care referral center, and has the
benefits of a large number of cases of high-risk histologic
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proportion of patients at risk for extra-nodal disease, we still
found an overall rate of CT scan in altering management of
patients of just 3%. This rate is likely to be lower in lower risk
populations and community settings. Finally, our study attempts
to quantify this utility of CT in identifying metastases in patients
with uterine cancer through a cost analysis model. Ultimately,
expenditure of $17,622 would be required to identify findings
that would alter management in just one patient.
The routine performance of preoperative staging CT for
patients with uterine corpus malignancies, especially for those
with endometrioid tumors, is of limited value. Routine pre-
operative CT is costly, and rarely alters treatment. Moreover, the
sensitivity of CT in predicting metastatic disease is low. Some
patients with high-risk histologic subtypes may benefit from
preoperative CT, since these tumors are traditionally more
aggressive in behavior and have a greater propensity of meta-
stases, but this ultimately requires further study. More recent
studies have investigated the utility of newer diagnostic moda-
lities such as combined PET/CT scan in preoperative staging of
patients with endometrial cancer, but since the treatment of most
patients includes comprehensive surgical staging, this approach
also remains in question.
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